The Food and Drug Administration on Wednesday approved MindMaze's upper-limb rehabilitation platform, MindMotion Pro.
The neuro-technology platform uses 3-D motion tracking cameras, creating a virtual reality environment to aid stroke patients and individuals with other traumatic injuries.
The platform maps patients' movements onto 3-D avatars and leads them through various rehabilitation exercises based on "standardized neurorehabilitation principles," according to a news release.
Patients can use the platform as soon as four days post-stroke.
More articles on supply chain:
Viewpoint: Why healthcare needs more 'me too' drugs
Viewpoint: Pharma should give trial participants a say in pricing new drugs
Magellan vein-based blood tests underreported lead levels, says health officials